Brian Johns
About Brian Johns
Brian Alvin Johns Chief Scientific Officer
Brian Alvin Johns currently serves as the Chief Scientific Officer. His role in this capacity involves leading scientific research and development, overseeing laboratory operations, and driving the strategic vision for new scientific initiatives. Johns brings extensive experience to his position, having previously served as Chief Scientific Officer at HemoShear Therapeutics, Inc. His leadership aids in bridging the gap between innovative scientific research and practical medical applications.
Brian Alvin Johns Education and Expertise
Brian Alvin Johns holds a Ph.D. in Chemistry, underscoring his deep expertise in the chemical sciences. His academic background provides a strong foundation for his career in medicinal chemistry and drug discovery. Throughout his career, Johns has made significant contributions to the development of critical medications, drawing from his extensive knowledge and experience in chemistry and pharmacology.
Brian Alvin Johns Professional Background
Before his current role, Brian Alvin Johns held several key positions in the pharmaceutical industry. He previously served as the Chief Scientific Officer at HemoShear Therapeutics, Inc., where he led scientific research efforts. Additionally, he was the Vice President of Discovery at both ViiV Healthcare and GlaxoSmithKline. In these roles, Johns drove major drug discovery projects and played a crucial part in advancing the company's research capabilities.
Brian Alvin Johns Contributions to Medicinal Chemistry
Throughout his career, Brian Alvin Johns has made substantial contributions to the field of medicinal chemistry. Notably, he played a significant role in the discovery of groundbreaking medications such as dolutegravir and cabotegravir. His work in drug discovery has earned him numerous honors and awards, recognizing his impact on the field. Johns also holds numerous patents and has published extensively, further contributing to advancements in medicinal chemistry.